scholarly journals Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn’s Disease

2017 ◽  
Vol 12 (4) ◽  
pp. 402-407 ◽  
Author(s):  
Amy L Lightner ◽  
Nicholas P McKenna ◽  
Chung Sang Tse ◽  
Neil Hyman ◽  
Radhika Smith ◽  
...  
2017 ◽  
Vol 47 (5) ◽  
pp. 573-580 ◽  
Author(s):  
A. L. Lightner ◽  
N. P. McKenna ◽  
C. S. Tse ◽  
L. E. Raffals ◽  
E. V. Loftus ◽  
...  

2019 ◽  
Vol 13 (11) ◽  
pp. 1433-1438 ◽  
Author(s):  
Geoffrey C Nguyen ◽  
Lillian Du ◽  
Rachel Y Chong ◽  
Timothy D Jackson

Abstract Background The inflammatory bowel diseases [IBD], including Crohn’s disease [CD] and ulcerative colitis [UC], frequently lead to bowel surgery. Hypoalbuminaemia has been shown to be a prognostic factor for outcomes following surgery for other indications, and we sought to determine its role in predicting IBD-related postoperative outcomes. Methods We included patients who underwent IBD-related major abdominal surgery in the American College of Surgeons’ National Surgical Quality Improvement Program [ACS-NSQIP] between 2005 and 2012. We assessed the impact of indicators of protein-energy malnutrition [PEM] including hypoalbuminaemia, weight loss, and body mass index on postoperative outcomes. Results We identified 10 913 IBD patients [6082 Crohn’s disease and 4831 ulcerative colitis] who underwent bowel surgery. The prevalence of modest and severe hypoalbuminaemia was 17% and 24%, respectively; 30-day mortality was higher in Crohn’s patients with modest and severe hypoalbuminaemia compared with those with normal albumin levels preoperatively [0.7% vs 0.2%, p <0.05; 2.4% vs 0.2%, p <0.01]. The same was true for patients with UC with modest and severe hypoalbuminaemia [0.9% vs 0.1%, p <0.01; 5.6% vs 0.1%, p <0.01]. Overall infectious complications were more common in the presence of severe hypoalbuminaemia for CD [20% vs 13%, p <0.01]. and UC [28% vs 15%, p <0.01] patients. Last, there were higher rates of extra-intestinal, non-septic complications in both CD and UC patients with hypoalbuminaemia compared with those with normal albumin levels. Conclusions This study suggests that moderate-severe hypoalbuminaemia is associated with worse IBD-related postoperative outcomes and may have a role in preoperative risk stratification.


2019 ◽  
Vol 62 (11) ◽  
pp. 1352-1362 ◽  
Author(s):  
Amy L. Lightner ◽  
Nicholas P. McKenna ◽  
Ahmad Alsughayer ◽  
William S. Harmsen ◽  
Kekoa Taparra ◽  
...  

2018 ◽  
Vol 154 (6) ◽  
pp. S-849
Author(s):  
Fares Ayoub ◽  
Amir Kamel ◽  
Naueen A. Chaudhry ◽  
Atif Iqbal ◽  
Sanda Tan ◽  
...  

2019 ◽  
Vol 1 (2) ◽  
Author(s):  
Amy L Lightner ◽  
Fabian Grass ◽  
Ahmad Alsughayer ◽  
Molly M Petersen ◽  
Laura E Raffals ◽  
...  

Abstract Introduction The impact of ustekinumab on adverse postoperative outcomes in Crohn’s disease (CD) remains largely unknown. We determined the difference in 90-day postoperative complication rates among CD patients exposed to ustekinumab within 12 weeks prior to an abdominal operation as compared to patients not exposed to biologic therapy. Methods A retrospective chart review of all adults with CD who underwent an abdominal operation between October 1, 2017 and December 31, 2018 at a single tertiary medical center was performed. Data collection included patient demographics, concurrent immunosuppression, serum laboratory values, operative values, and 90-day outcomes including superficial surgical site infection (sSSI), intra-abdominal sepsis, overall infectious complications, readmission, and reoperation rates. The primary outcome was the 90-day rate of intra-abdominal sepsis. Results Fifty-seven CD patients received ustekinumab and 277 received no biologic therapy in the 12 weeks prior to major abdominal surgery. Ustekinumab-exposed patients were younger, less likely to have diabetes mellitus or active tobacco exposure, were more often obese, and more often taking a concurrent immunomodulator. Ustekinumab remained an independent predictor of intra-abdominal sepsis on multivariable logistic regression. Immunomodulator exposure was associated with significantly increased rates of sSSI and overall complication rates. Conclusions Ustekinumab is associated with increased rates of 90-day postoperative intra-abdominal sepsis following a major abdominal operation for CD.


2015 ◽  
Vol 148 (4) ◽  
pp. S-232
Author(s):  
Azah Althumairi ◽  
Jonathan E. Efron ◽  
Brindusa Truta ◽  
Joseph K. Canner ◽  
Susan Gearhart ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document